Legal Briefs: Concordia/Par And FTC; Amgen Off-Label Compendium Settlement
Executive Summary
FTC objected to atypical Concordia deal with Par not to launch an authorized generic in return for share of profits on Par’s generic; Amgen settlement with 49 states restricts interactions with compendium.
You may also be interested in...
Amgen Off-label Settlement Includes Exec Oversight Of Individual Product Compliance
Amgen pled guilty to off-label promotion of Aranesp, and settled civil claims of kickbacks, false price reporting and off-label promotion of other drugs; Sanofi settles claims it provided kickbacks in the form of free Hyalgan samples.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.